Pain Therapeutics (NASDAQ:PTIE) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, Bloomberg Earnings reports.

TRADEMARK VIOLATION NOTICE: This report was first reported by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.watchlistnews.com/pain-therapeutics-ptie-releases-quarterly-earnings-results/1674131.html.

A number of research firms recently issued reports on PTIE. Zacks Investment Research downgraded Pain Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 19th. Gabelli downgraded Pain Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, July 17th.

About Pain Therapeutics

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Earnings History for Pain Therapeutics (NASDAQ:PTIE)

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.